Oral Dissolving Film of Rivastigmine: Optimization Using Factorial Design
Purpose Due to impairments in memory and judgment, it is difficult for dementia patients to understand why they need medicine. Moreover, they often have swallowing difficulties. In this investigation, an oral dissolving film of rivastigmine tartrate (RT-ODF) was developed, offering a unique and convenient formulation for dementia patients. Methods RT-ODF was developed using a solvent-casting technique. Sodium alginate and sodium carboxymethyl cellulose were used as film-forming polymers, and glycerol was used as a plasticizer. A full factorial design ($ 3^{2} $) was employed to estimate the impact of two factors at three levels: polymer concentration (1, 1.5, and 2% w/v) and plasticizer concentration (30, 40, and 50% w/v) on the responses, i.e., the tensile strength (TS), the disintegration time (DT), and the quantity of drug released (Q10 min). Results The optimized formula (A1) that had the highest desirability value (0.923) exhibited the lowest tensile strength (3.67 ± 0.72 MPa), the shortest disintegration time (20 ± 2.0 s), and the highest percentage of drug released after 10 min (97.12 ± 2.01%). It was composed of 1% w/v sodium alginate (ALG-Na) and plasticized with 30% w/v glycerol. The pharmacokinetic study revealed that the RT-ODFs enhanced the drug’s bioavailability by 1.91-fold relative to the reference product (Exelon® capsule). Conclusion Oral dissolving films of rivastigmine tartrate could be a promising approach to promote drug bioavailability and convenience for geriatric patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical innovation - 18(2023), 4 vom: 01. Aug., Seite 1892-1907 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Farghaly, Dalia A. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
3 |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s12247-023-09743-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054307864 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054307864 | ||
| 003 | DE-627 | ||
| 005 | 20240109064654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240109s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12247-023-09743-4 |2 doi | |
| 035 | |a (DE-627)SPR054307864 | ||
| 035 | |a (SPR)s12247-023-09743-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Farghaly, Dalia A. |e verfasserin |0 (orcid)0000-0002-1937-1579 |4 aut | |
| 245 | 1 | 0 | |a Oral Dissolving Film of Rivastigmine: Optimization Using Factorial Design |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Purpose Due to impairments in memory and judgment, it is difficult for dementia patients to understand why they need medicine. Moreover, they often have swallowing difficulties. In this investigation, an oral dissolving film of rivastigmine tartrate (RT-ODF) was developed, offering a unique and convenient formulation for dementia patients. Methods RT-ODF was developed using a solvent-casting technique. Sodium alginate and sodium carboxymethyl cellulose were used as film-forming polymers, and glycerol was used as a plasticizer. A full factorial design ($ 3^{2} $) was employed to estimate the impact of two factors at three levels: polymer concentration (1, 1.5, and 2% w/v) and plasticizer concentration (30, 40, and 50% w/v) on the responses, i.e., the tensile strength (TS), the disintegration time (DT), and the quantity of drug released (Q10 min). Results The optimized formula (A1) that had the highest desirability value (0.923) exhibited the lowest tensile strength (3.67 ± 0.72 MPa), the shortest disintegration time (20 ± 2.0 s), and the highest percentage of drug released after 10 min (97.12 ± 2.01%). It was composed of 1% w/v sodium alginate (ALG-Na) and plasticized with 30% w/v glycerol. The pharmacokinetic study revealed that the RT-ODFs enhanced the drug’s bioavailability by 1.91-fold relative to the reference product (Exelon® capsule). Conclusion Oral dissolving films of rivastigmine tartrate could be a promising approach to promote drug bioavailability and convenience for geriatric patients. | ||
| 650 | 4 | |a Alzheimer’s disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rivastigmine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Geriatric patients |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oral dissolving film |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Patient compliance |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a 3 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Factorial design |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Afifi, Samar A. |4 aut | |
| 700 | 1 | |a Aboelwafa, Ahmed A. |4 aut | |
| 700 | 1 | |a Mohamed, Magdy I. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical innovation |d New York, NY : Springer, 2006 |g 18(2023), 4 vom: 01. Aug., Seite 1892-1907 |w (DE-627)SPR024593338 |w (DE-600)2428208-X |x 1939-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:4 |g day:01 |g month:08 |g pages:1892-1907 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12247-023-09743-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 4 |b 01 |c 08 |h 1892-1907 | ||